Director/PDMR Shareholding

RNS Number : 7375Z
GlaxoSmithKline PLC
16 March 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr M M Slaoui

b)

Position/status

Chairman, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

An increase of 4 ADSs following the notional allocation of ADSs on 15 March 2017, at a price of $42.00 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$42.00

4

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-03-15

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr K Slaoui

b)

Position/status

PCA of Dr M M Slaoui (Chairman, Global Vaccines)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

An increase of 91 ADSs following the notional allocation of ADSs on 15 March 2017, at a price of $42.00 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$42.00

91

   

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-03-15

f)

Place of the transaction

 

n/a

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHQQLFFDXFFBBF

Companies

GSK (GSK)
UK 100

Latest directors dealings